In contrast, patients with high-risk NB die because of the tumor despite multimodal therapy including chemotherapy.2 Accumulated evidence demonstrate that MYCN amplification,3, 4anaplastic lymphoma kinase (ALK) mutation or amplification5, 6, 7, 8 and downregulation of the gene encoding nerve growth factor receptor (TrkA)9, 10, 11 has critical roles in unfavorable NB. The gene discussed is NGFR; the disease is neuroblastoma.